Current Liabilities

Accrued Contingent Liabilities

Moderna Accrued Contingent Liabilities increased by 497.5% to $950.00M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ1 2021
Last reportedQ1 2026May 1, 2026

How to read this metric

An increase suggests higher legal or operational risk, while a decrease may indicate the resolution of past uncertainties.

Detailed definition

This represents the estimated financial obligations arising from past events where the outcome is uncertain but probable...

Peer comparison

Peers typically disclose these in legal contingencies footnotes; high levels relative to equity can signal significant litigation exposure.

Metric ID: accrued_contingent_liabilities

Historical Data

2 periods
 Q1 '22Q1 '26
Value$159.00M$950.00M
QoQ Change+497.5%
Range$159.00M$950.00M

Accrued Contingent Liabilities at Other Companies

Frequently Asked Questions

What is Moderna's accrued contingent liabilities?
Moderna (MRNA) reported accrued contingent liabilities of $950.00M in Q1 2026.
What does accrued contingent liabilities mean?
The amount of money set aside to cover potential future losses from uncertain events like legal disputes.